Skip to main content
Premium Trial:

Request an Annual Quote

Pronota Signs Agreement with Molecuence to Develop Protein Biomarkers for Stroke

Premium

Belgian protein biomarker firm Pronota said this week it has signed an agreement with Molecuence Corporation – a wholly owned subsidiary of Mitsubishi Chemical – to discover and validate protein biomarkers in stroke.

Pronota will use its proprietary biomarker discovery platform MASStermind and verification platform MASSterclass on the project, the financial terms of which were not disclosed.

According to the company, its MASStermind system streamlines biomarker development by selecting for analysis only the N-terminal tryptic peptides of each protein, thereby significantly reducing sample complexity. The MASSterclass verification platform then uses multiple-reaction monitoring mass spectrometry to do targeted analysis of putative biomarkers.

Broadly speaking, this two-stage process coupling mass spec-based biomarker discovery with a targeted MRM-MS verification step is similar to a workflow for discovery and verification of stroke-related biomarkers currently under development by scientists from Thermo Fisher Scientific's BRIMS Center (See story this issue). That project is proceeding in collaboration with researchers at Massachusetts General Hospital.

In addition to mass spec-based biomarker discovery, Pronota is also working on antibody-based diagnostics for diseases including heart failure, kidney failure, preeclampsia, sepsis, and ovarian cancer. Last June the company completed a proof-of-concept study using aptamers to bind target proteins, which they then quantified by sequencing the bound aptamers using next-generation sequencing technology (PM 06/04/2010).

The company has filed two patents based on that research and is currently exploring the use of NGS to improve aptamer generation.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.